HTGMQ — HTG Molecular Diagnostics Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $0.33m
- $6.37m
Annual cashflow statement for HTG Molecular Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.5 | -19.3 | -20.9 | -17.1 | -21.6 |
| Depreciation | |||||
| Non-Cash Items | 2.2 | 2.15 | 3.46 | 0.93 | 2.74 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.387 | -0.811 | -0.229 | -1.01 | -0.139 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -13.2 | -16.7 | -16.3 | -16.5 | -18.4 |
| Capital Expenditures | -0.95 | -1.1 | -0.454 | -0.644 | -0.023 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -22.3 | -2.4 | 19.2 | -6.02 | 12.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -23.2 | -3.5 | 18.7 | -6.66 | 12.4 |
| Financing Cash Flow Items | 0.124 | -0.116 | 7.57 | 10.8 | 9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 38.1 | 19.4 | 9.05 | 10.4 | 8.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.73 | -0.813 | 11.5 | -12.8 | 2.61 |